Your genes may hold the key to your heart Drug's success
NCT ID NCT07408427
Summary
This study aims to understand why a heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than others. Researchers will follow 140 adults with HCM to see if the specific gene causing their condition or a gene that affects how the body processes medicine influences their response to the drug. The goal is to help doctors better predict who will benefit most from this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester Centre for Genomic Medicine (MCGM)
Multiple Locations, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.